Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Doxycycline hyclate
Drug ID BADD_D00727
Description Doxycycline is a broad-spectrum antibiotic synthetically derived from oxytetracycline [FDA label]. This drug is a second-generation tetracycline, exhibiting lesser toxicity than first-generation tetracyclines [A174034]. Doxycycline may be used to treat a wide range of bacterial infections, depending on the results of antibiotic susceptibility testing.
Indications and Usage Doxycycline is indicated for the treatment of various infections by gram-positive and gram-negative bacteria, aerobes and anaerobes, as well other types of bacteria. A complete list of organisms is available in the FDA label and in the "indications" section of this drug entry [FDA label]. The following are some of the major infections that may be treated with doxycycline [FDA label]: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis Psittacosis (ornithosis) caused by Chlamydia psittaci Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis Nongonococcal urethritis caused by Ureaplasma urealyticum Relapsing fever due to Borrelia recurrentis **A note regarding anti-microbial resistance** It is important to note that doxycycline is not the drug of choice in the treatment of any type of staphylococcal infection. Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Streptococcus faecalis have been found to be resistant to tetracyclines. Therefore, tetracyclines such as doxycycline should not be used to treat streptococcal infections unless the microorganism has been demonstrated to be susceptible [FDA label].
Marketing Status approved; investigational; vet_approved
ATC Code A01AB22; J01AA02
DrugBank ID DB00254
KEGG ID D02129
MeSH ID D004318
PubChem ID 54705095
TTD Drug ID D0S0LZ
NDC Product Code 72789-319; 83112-985; 51552-0852; 71052-030; 27241-154; 0143-9803; 50090-4981; 50090-6134; 51862-557; 51862-709; 53489-118; 55289-502; 62135-596; 62135-626; 63739-168; 67296-1743; 68308-716; 70518-3135; 70518-3213; 70518-3363; 71205-554; 72789-298; 0904-0428; 82982-048; 0069-0950; 51473-0501; 71057-3440; 46708-484; 62135-625; 62332-362; 67296-1811; 67405-550; 68071-5232; 69668-515; 70518-3695; 71205-653; 0591-4550; 0591-5553; 11014-0091; 62991-2572; 67698-101; 23155-611; 0143-3142; 43063-999; 43547-462; 46708-499; 50268-279; 60760-651; 61919-082; 62135-985; 62332-388; 68071-2787; 68999-984; 70771-1104; 70771-1588; 70934-810; 71335-1549; 71335-2086; 60219-2132; 60429-069; 60760-215; 62332-363; 62332-484; 69263-501; 70518-3214; 70934-187; 70934-987; 70934-995; 0591-4575; 72143-211; 72789-277; 80425-0114; 80425-0211; 50546-560; 24658-312; 27241-140; 0143-2112; 45865-116; 46708-481; 46708-482; 50090-5380; 53489-120; 55154-7128; 55289-866; 62332-387; 63187-818; 63187-845; 68047-714; 68071-5265; 68788-7638; 71205-156; 71205-697; 71335-1464; 72578-054; 0904-0430; 27241-153; 40032-794; 42806-312; 50090-5825; 51407-298; 51862-695; 59115-123; 60505-4384; 62332-482; 68071-2777; 68071-3466; 68071-4950; 68788-8217; 70518-1627; 70934-951; 71205-518; 71335-1686; 71610-117; 80425-0280; 51927-0130; 60592-201; 27808-234; 42708-173; 43063-988; 43547-325; 46708-388; 50090-6212; 60687-513; 60760-626; 62135-623; 62332-352; 62332-353; 62332-481; 62332-483; 62332-499; 63187-942; 67296-1801; 68071-4836; 68382-708; 68788-8464; 71335-1768; 72189-127; 72578-001; 72789-276; 82982-060; 10695-103; 50909-8105; 55488-0100; 23155-141; 23155-143; 0143-3141; 50090-6036; 50090-6133; 51655-998; 51862-558; 53489-119; 67296-1456; 68071-5259; 68308-715; 68382-222; 68382-710; 68999-625; 68999-626; 68999-985; 70771-1358; 70771-1359; 70771-1589; 71335-2179; 71335-9718; 72578-055; 82982-053; 51552-1577; 51927-3129; 46708-352; 46708-387; 50090-4867; 50090-5560; 50268-278; 51655-478; 51862-696; 53489-647; 55154-8079; 55700-732; 60505-4382; 62135-984; 62584-693; 68308-775; 68382-221; 69489-111; 70518-3039; 71335-2113; 72789-309; 76420-044; 11014-0090; 11014-0235; 38779-0434; 59929-344; 23155-142; 27241-141; 43386-794; 0143-9802; 43547-324; 45865-444; 46708-483; 50268-277; 53002-2711; 68382-709; 70518-1248; 70518-3706; 70771-1587; 71335-1316; 47621-018; 55018-151; 16110-601; 42192-501; 42806-362; 46708-353; 50090-0023; 50090-5588; 51862-559; 51862-560; 51862-571
UNII 19XTS3T51U
Synonyms Doxycycline | Doxycycline Monohydrate | Vibramycin | Atridox | Doxycycline Phosphate (1:1) | BMY-28689 | BMY 28689 | BMY28689 | BU-3839T | BU 3839T | BU3839T | Doryx | Doxycycline Calcium Salt (1:2) | Doxycycline Hyclate | Doxycycline Hemiethanolate | Doxycycline Monohydrochloride, 6-epimer | Doxycycline Monohydrochloride, 6 epimer | Doxycycline Monohydrochloride, Dihydrate | Doxycycline Calcium | 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S-(4alpha,4aalpha,5alpha,5aalpha,6alpha,12aalpha))- | Alpha-6-Deoxyoxytetracycline | Alpha 6 Deoxyoxytetracycline | Doxycycline-Chinoin | Doxycycline Chinoin | Hydramycin | Oracea | Periostat | Vibra-Tabs | Vibra Tabs | Vibramycin Novum | Vibravenos
Chemical Information
Molecular Formula C24H33ClN2O10
CAS Registry Number 24390-14-5
SMILES CCO.CC1C2C(C3C(C(=O)C(=C(C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O.Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Vulvovaginal candidiasis11.03.03.005; 21.14.02.003---
Osteopenia14.04.04.004; 15.02.03.003---
Necrotising colitis07.08.01.013---
Musculoskeletal discomfort15.03.04.001---
Epidermal necrosis23.03.03.035---
Inflammation08.01.05.007; 10.02.01.089---
Decreased appetite08.01.09.028; 14.03.01.005--
Sinus operation25.05.05.001---
Tooth fracture07.09.05.008; 12.01.17.024---
Vulvovaginal mycotic infection11.03.05.004; 21.14.02.004---
Bone loss15.02.04.020---
Oropharyngeal discomfort07.05.05.008; 22.12.03.015---
Oropharyngeal pain07.05.05.004; 22.12.03.016--
Upper-airway cough syndrome22.12.03.036--
Gingival discomfort07.09.13.003---
Heavy menstrual bleeding21.01.03.005---
Hyperaesthesia teeth07.09.06.005---
Idiopathic intracranial hypertension17.07.02.011---
The 4th Page    First    Pre   4    Total 4 Pages